Unlocking Undruggable Targets
with Smart Peptides

SPIMA Therapeutics develops smart peptide-based immunotherapies to address currently undruggable targets bringing innovative treatments to patients facing aggressive pathologies with limited therapeutic options today

About Us

 

SPIMA Therapeutics, a Landmark BioVentures Company

Spima background
Most targets are considered “undruggable” due to various factors, limiting the development of effective treatments for aggressive pathologies

 

Adapted from: Neklesa, et al. 2017

 

At SPIMA, we aim to overcome these limitations by advancing novel stapled peptides as first-in-class therapeutics to address inflammatory and neoplastic disorders